Gammagard Liquid
Generic name:immune globulin g (human)
Dosage form: injection, solution
Drug class:Immune globulins
Medically reviewed by Drugs.com. Last updated on Mar 1, 2021.
On This Page
WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE
- ▪
- Thrombosis may occur with immune globulin products, including Gammagard Liquid. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.4), Patient Counseling Information (17)].
- ▪
- Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Gammagard Liquid does not contain sucrose.
- ▪
- For patients at risk of thrombosis, administer Gammagard Liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity [see Dosage and Administration (2.3) and Warnings and Precautions (5.4)].
